CN106038570A - 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物 - Google Patents

能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物 Download PDF

Info

Publication number
CN106038570A
CN106038570A CN201610390867.1A CN201610390867A CN106038570A CN 106038570 A CN106038570 A CN 106038570A CN 201610390867 A CN201610390867 A CN 201610390867A CN 106038570 A CN106038570 A CN 106038570A
Authority
CN
China
Prior art keywords
coagulopathy
prostacyclin
medicine
syndecan
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610390867.1A
Other languages
English (en)
Chinese (zh)
Inventor
佩尔·约翰松
西塞·赖伊·奥斯特洛夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H S RIGSHOSPITALET
Original Assignee
H S RIGSHOSPITALET
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H S RIGSHOSPITALET filed Critical H S RIGSHOSPITALET
Publication of CN106038570A publication Critical patent/CN106038570A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201610390867.1A 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物 Pending CN106038570A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070427 2010-10-01
DKPA201070427 2010-10-01
CN201180057292.7A CN103238070B (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180057292.7A Division CN103238070B (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Publications (1)

Publication Number Publication Date
CN106038570A true CN106038570A (zh) 2016-10-26

Family

ID=44872128

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610390867.1A Pending CN106038570A (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物
CN201180057292.7A Expired - Fee Related CN103238070B (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180057292.7A Expired - Fee Related CN103238070B (zh) 2010-10-01 2011-09-30 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物

Country Status (9)

Country Link
US (1) US20130261177A1 (cg-RX-API-DMAC7.html)
EP (1) EP2622354A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013543491A (cg-RX-API-DMAC7.html)
KR (1) KR20140025303A (cg-RX-API-DMAC7.html)
CN (2) CN106038570A (cg-RX-API-DMAC7.html)
AU (1) AU2011307494B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013007849A2 (cg-RX-API-DMAC7.html)
CA (1) CA2812846A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012041334A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722812A (zh) * 2013-11-13 2016-06-29 开曼化学股份有限公司 前列环素类似物的胺盐
US10450257B2 (en) 2012-12-07 2019-10-22 Cayman Chemical Company Incorporated Methods of synthesizing a prostacyclin analog

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
KR20140053881A (ko) * 2011-04-19 2014-05-08 릭스하스피탈렛 모세관 누출의 예방 및 치료를 위한 수술 동안 투여되는 프로스타시클린 및 그 유사체
EP2834642A1 (en) * 2012-03-30 2015-02-11 Rigshospitalet Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) * 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
WO2016073668A1 (en) 2014-11-06 2016-05-12 The Regents Of The University Of Colorado Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN107430136A (zh) * 2015-02-03 2017-12-01 科罗拉多州立大学董事会,公司实体 粘弹性分析用于预测大量出血的用途
DK3278112T3 (da) 2015-03-29 2021-12-13 Endothel Pharma Aps Sammensætning, der omfatter prostacyclin eller analoger deraf, til behandling af akut, kritisk syge patienter
WO2016200765A1 (en) 2015-06-08 2016-12-15 The Regents Of The University Of Colorado, A Body Corporate Time independent viscoelastic analysis parameter for prediction of patient outcome
US11169142B2 (en) 2016-05-11 2021-11-09 The Regents Of The University Of Colorado, A Body Corporate Viscoelastic analysis in patients with disease associated with cardiovascular system
US10806801B2 (en) * 2017-06-07 2020-10-20 National Cheng Kung University Pharmaceutical composition and methods for using the same
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
US12440285B2 (en) * 2021-01-22 2025-10-14 Cilag Gmbh International Prediction of hemostasis issues based on biomarker monitoring
US12105099B2 (en) * 2021-04-28 2024-10-01 Diotex Diagnostics, Llc Methods and devices for quantitatively estimating syndecan-1
CN114113641B (zh) * 2021-10-28 2023-11-03 中科精瓒(武汉)医疗技术有限公司 一种活化凝血检测试剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075861A2 (en) * 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58164512A (ja) * 1982-03-25 1983-09-29 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤
AU4405293A (en) * 1992-06-05 1994-01-04 Barbara M. Alving Test for quantitative thrombin time
JPH11322612A (ja) * 1998-03-13 1999-11-24 Toray Ind Inc 肝細胞増殖因子誘引剤
CN2757804Y (zh) * 2004-11-19 2006-02-15 杨俊玉 心脏按压复苏指示装置
EP2063273A1 (en) * 2007-11-21 2009-05-27 Pentapharm GmbH Method for assessing the fibrinogen contribution in coagulation
US20100144597A1 (en) * 2008-12-10 2010-06-10 Ward Kevin R Novel combinatorial approaches to enhancing oxygen transport to tissues
ES2477498T3 (es) * 2010-01-20 2014-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Proteína 4 del tipo angiopoyetina (ANGPTL4) para el mantenimiento de la integridad de la barrera celular del endotelio vascular

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075861A2 (en) * 2008-12-30 2010-07-08 Thrombologic Aps Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10450257B2 (en) 2012-12-07 2019-10-22 Cayman Chemical Company Incorporated Methods of synthesizing a prostacyclin analog
CN105722812A (zh) * 2013-11-13 2016-06-29 开曼化学股份有限公司 前列环素类似物的胺盐
CN105722812B (zh) * 2013-11-13 2018-11-16 开曼化学股份有限公司 前列环素类似物的胺盐
US10155716B2 (en) 2013-11-13 2018-12-18 Cayman Chemical Company Incorporated Amine salts of a prostacyclin analog

Also Published As

Publication number Publication date
BR112013007849A2 (pt) 2016-06-07
EP2622354A1 (en) 2013-08-07
JP2013543491A (ja) 2013-12-05
WO2012041334A1 (en) 2012-04-05
KR20140025303A (ko) 2014-03-04
CN103238070B (zh) 2016-06-29
CA2812846A1 (en) 2012-04-05
AU2011307494A1 (en) 2013-05-02
CN103238070A (zh) 2013-08-07
US20130261177A1 (en) 2013-10-03
AU2011307494B2 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
CN103238070B (zh) 能够调节/保护内皮完整性的用于预防或治疗急性创伤性凝血病和心脏骤停复苏的化合物
US20150057325A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Boyer et al. Postoperative acute kidney injury
Oliver et al. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT)
TARASEVICIENE‐STEWART et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension
ES2670711T3 (es) Receptor soluble del activador de plasminógeno de tipo uroquinasa (suPAR) como marcador de diagnóstico de inflamación de grado bajo
JP2014514310A (ja) 毛細血管漏出の予防及び治療のために手術時に投与されるプロスタサイクリン及びその類似体
US20250304671A1 (en) Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment
Hein et al. Functional and molecular characterization of the endothelin system in retinal arterioles
Gabrielli et al. Systemic oxidative stress and endothelial dysfunction is associated with an attenuated acute vascular response to inhaled prostanoid in pulmonary artery hypertension patients
ES2898424T3 (es) Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo
Tkachenko et al. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease
Serebruany et al. Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial
BR112020023943A2 (pt) métodos de tratamento de pacientes em risco de lesão renal e insuficiência renal
HUE033204T2 (en) Factor II alone or in combination with additional factor for the treatment of impaired haemostasis associated with diluted coagulopathy
Tang et al. Prenatal betamethasone exposure alters renal function in immature sheep: sex differences in effects
Wimmer et al. Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure
Boldt et al. RETRACTED: Volume Replacement With a Balanced Hydroxyethyl Starch (HES) Preparation in Cardiac Surgery Patients
RU2423692C2 (ru) Вещества для профилактики и лечения панкреатита
O'CONNOR et al. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol
WO2023061946A1 (en) Use of trem-1 for predicting and preventing postoperative complications after cardiac surgery with cardiopulmonary by-pass
EP3999104A1 (en) Use of recombinant adamts13 for treating sickle cell disease
Gallieni et al. Impaired brachial artery endothelial flow-mediated dilation and orthostatic stress in hemodialysis patients
WO2010149172A2 (en) SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
Burkard et al. Endothelial barrier dysfunction, loss of microcirculatory flow and organ failure in sepsis: current clinical view of sepsis and links to basic research

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161026

WD01 Invention patent application deemed withdrawn after publication